# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Brandon Couillard initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Overweight rating and announ...
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first...
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, ...
Benchmark analyst Bruce Jackson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $91 to $67.